Ventyx Biosciences Inc (VTYX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ventyx Biosciences Inc (VTYX) has a cash flow conversion efficiency ratio of -0.091x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.51 Million) by net assets ($191.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Ventyx Biosciences Inc to measure how much of total assets are equity-financed.
Ventyx Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Ventyx Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore VTYX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Ventyx Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ventyx Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KPC Pharmaceuticals Inc
SHG:600422
|
-0.002x |
|
Bonheur
OL:BONHR
|
0.082x |
|
HyUnion Holding Co Ltd
SHE:002537
|
0.017x |
|
Scandi Standard publ AB
ST:SCST
|
0.111x |
|
Techwing Inc
KQ:089030
|
0.014x |
|
Shandong Laiwu Jinlei Wind Power Technology Co Ltd
SHE:300443
|
0.014x |
|
NB Bancorp, Inc. Common Stock
NASDAQ:NBBK
|
0.028x |
|
Jiangsu Maixinlin Aviation Science & Technology Corp. A
SHG:688685
|
0.244x |
Annual Cash Flow Conversion Efficiency for Ventyx Biosciences Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Ventyx Biosciences Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Ventyx Biosciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $254.04 Million | $-130.87 Million | -0.515x | +24.54% |
| 2023-12-31 | $243.92 Million | $-166.52 Million | -0.683x | -144.60% |
| 2022-12-31 | $353.89 Million | $-98.77 Million | -0.279x | -101.61% |
| 2021-12-31 | $279.20 Million | $-38.65 Million | -0.138x | -168.50% |
| 2020-12-31 | $-30.65 Million | $-6.20 Million | 0.202x | -68.42% |
| 2019-12-31 | $-4.13 Million | $-2.64 Million | 0.640x | -- |
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a sele… Read more